Terapi Kanker Payudara Stadium Lanjut HER2 (+)
DOI:
https://doi.org/10.55175/cdk.v50i10.915Keywords:
HER2, breast cancer, advanced stageAbstract
Approximately 15-20% of breast cancers harbor human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. This subtype of breast cancer is associated with aggressive behavior, high recurrence rates, and worse prognosis. However, with the introduction of HER2-targeted therapy, trastuzumab, the survival rates have greatly improved. In patients with HER2 positive advanced disease, taxane in combination with trastuzumab and pertuzumab is given in the first-line setting. In the second-line setting and beyond, several emerging anti-HER2 therapies are becoming available including trastuzumab deruxtecan, tucatinib, T-DM1, neratinib, lapatinib, pyrotinib, margetuximab.
Downloads
References
Martinez-Saez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17:594-604.
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70:355-74.
Bartelemy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE. Pertuzumab: Development beyond breast cancer. Anticancer Res. 2014;34:1483-92.
Landaverde D, Verma S. Recent treatment advances in HER2-positive metastatic breast cancer: A clinical approach. Clin Pract. 2012;9(3):287-99.
Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open 2022 doi: 10.1016/j.esmoop.2021.100343.
Swain SM, Baselga J, Kim SB, Ro JS, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-34.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-30.
Martinez MT, Perez-Fidalgo JA, Martin-Martorell P, Cejalvo JM, Pons V, Bermejo B, et al. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Crit Rev Oncol/Hematol. 2016;97:96-106.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743-54.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
Li LX, Zhang D, Liu BL, Lv D, Zhai JT, Guan XW, et al. Antibody-drug conjugates in HER2-positive breast cancer. Chinese Medical Journal 2022;135(3):261-7.
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on trastuzumab deruxtecan (DS-8201, T-DXd) for HER2 mutation positive non-small cell lung cancer. Lung Cancer: Targets and Therapy 2021;12:103-14.
Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Ann Pharmacother. 2021 doi: 10.1177/1060028021998320.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;402:105-17.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
Trastuzumab deruxtecan. Product Information [FDA]. 2022 [cited 2022 May 29]. Available from: www.fda.gov.
Jacobson A. Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases. The Oncologist 2022;27(Suppl 1):S3-4.
Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12:1-9.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
Shah M, Wedam S, Cheng J, Fiero MH, Xia HM, Li F, et al. FDA approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:1220-6.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38:3138-49.
Xu BH, Yan M, Hu XC, Feng JF, Ouyang QC, Tong ZS, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicenter, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351-60.
Blair HA. Pyrotinib: First global approval. Drugs 2018 doi: 10.1007/s40265-018-0997-0.
Schlam I, Nunes R, Lynce F. Profile of margetuximab: Evidence to date in the targeted treatment of metastatic HER2-positive breast cancer. Onco Targets and Therapy 2022;15:471-8.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 doi: 10.1200/JCO.21.02937.
NCCN clinical practice guidelines in oncology. Breast cancer. Version 4.2023 [cited 2023 May 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:2612-35.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
